Guest writer Joanna Buoniconti says that new treatments have granted her many things she's grateful for, including the ...

New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMANew analyses from DEVOTE Part C further characterize the improvements in motor function ...

How many individuals have been treated with SPINRAZA worldwide? Over 14,000 individuals have been treated with SPINRAZA across more than 71 countries, spanning different ages and SMA types.

Biogen said salanersen uses the same mechanism of action as its Spinraza drug for SMA but is designed to achieve greater potency, giving it the potential to achieve high efficacy and enable once ...

Biogen shared Phase I trial results, highlighting the potential benefits of the SMA treatment while promoting its once-yearly dosing schedule.

Biogen’s Spinraza follow-up helps children with SMA who didn’t benefit from Zolgensma ...

SPINRAZA has shown efficacy across ages and SMA types with a well-established safety profile based on data in patients treated up to 10 years, combined with unsurpassed real-world experience.

Biogen’s antisense oligonucleotide (ASO), salanersen, is advancing to Phase III trials after it showed benefit with a lower dosing schedule than Spinraza (nusinersen) in patients with spinal muscular ...

Many SMA patients continue to see gains in motor function with long-term Spinraza treatment, a real-world study from Switzerland reported.